GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sigyn Therapeutics Inc (OTCPK:SIGY) » Definitions » Deferred Policy Acquisition Costs

SIGY (Sigyn Therapeutics) Deferred Policy Acquisition Costs


View and export this data going back to 2016. Start your Free Trial

What is Sigyn Therapeutics Deferred Policy Acquisition Costs?

Deferred Policy Acquisition Costs only applies to banks and insurance companies.


Sigyn Therapeutics Business Description

Industry
Traded in Other Exchanges
N/A
Address
2468 Historic Decatur Road, Suite 140, San Diego, CA, USA, 92106
Sigyn Therapeutics Inc is a development-stage therapeutic technology company. Its business focus is the clinical advancement of Sigyn Therapy, a multi-function blood purification technology designed to overcome the limitations of previous drugs and devices to treat life-threatening inflammatory disorders, including sepsis, the cause of hospital deaths world-wide. To support widespread implementation, the company designed Sigyn Therapy to be a single-use disposable device that is deployable on the world-wide infrastructure of hemodialysis and continuous renal replacement therapy machines already located in hospitals and clinics.
Executives
Joseph Segelman director, 10 percent owner, officer: President & CEO 9190 W OLYMPIC BLVD, # 263, BEVERLY HILLS CA 90212
Australian Sapphire Corp 10 percent owner 9190 W OLYMPIC BLVD, BEVERLY HILLS CA 90212
Chaya Segelman director, officer: Secretary 9190 W OLYMPIC BLVD, # 263, BEVERLY HILLS CA 90212